FENC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fennec Pharmaceuticals Inc (FENC) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company shows strong revenue growth potential, positive analyst sentiment, and a unique product with no direct competitors. Despite recent net income losses, the growth trajectory and market opportunity outweigh the risks for long-term investors.
The technical indicators suggest a neutral to slightly bullish trend. The MACD is positive and contracting, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the RSI is neutral at 50.167. The stock is trading near its pivot point of 8.614, with support at 8.138 and resistance at 9.09.
Analysts have initiated coverage with strong buy ratings and high price targets ($16-$18), citing the unique market position of Pedmark and its significant revenue growth potential.
Recent study highlights the safety and efficacy of Pedmark, enhancing its clinical feasibility and market appeal.
Revenue increased by 78.69% YoY in Q3 2025, indicating strong growth momentum.
Net income and EPS have significantly declined YoY, with net income dropping by -88.88% and EPS by -90.48%.
No significant hedge fund or insider trading trends, indicating limited institutional interest currently.
In Q3 2025, revenue increased by 78.69% YoY to $12.46M, showcasing strong growth. However, net income dropped by -88.88% YoY to -$638,000, and EPS fell by -90.48% YoY to -0.02. Gross margin improved to 94.7%, up 17.58% YoY, reflecting operational efficiency.
Analysts are highly bullish on FENC. B. Riley and Piper Sandler initiated coverage with Buy and Overweight ratings, respectively, and price targets of $16-$18. Analysts emphasize the company's strong revenue growth potential, unique product positioning, and lack of competition in its therapeutic category.
